Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.68−0.07 (-8.81%)
Close on Nov 12, 2026Market cap $22.22MP/E –Yield –
Celularity total assets
Total assets on the balance sheet at the end of each period.
Celularity's total assets was $96.17M at Jun 30, 2026. For fiscal 2025 it was $107.33M, down 19.1% from the year before. The highest annual figure on record is $431.01M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.33M | -19.1% |
| FY2024 | Dec 31, 2024 | $132.68M | -7.8% |
| FY2023 | Dec 31, 2023 | $143.89M | -64.1% |
| FY2022 | Dec 31, 2022 | $401.07M | -3.2% |
| FY2021 | Dec 31, 2021 | $414.13M | -3.9% |
| FY2020 | Dec 31, 2020 | $431.01M | +47.8% |
| FY2019 | Dec 31, 2019 | $291.61M | +167050.3% |
| FY2018 | Dec 31, 2018 | $174.46K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $96.17M | -20.0% |
| Q1 FY2026 | Mar 31, 2026 | $99.48M | -22.8% |
| Q4 FY2025 | Dec 31, 2025 | $107.33M | -19.1% |
| Q3 FY2025 | Sep 30, 2025 | $114.24M | -11.3% |
| Q2 FY2025 | Jun 30, 2025 | $120.28M | -11.2% |
| Q1 FY2025 | Mar 31, 2025 | $128.88M | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $132.68M | -7.8% |
| Q3 FY2024 | Sep 30, 2024 | $128.84M | -18.0% |
| Q2 FY2024 | Jun 30, 2024 | $135.49M | -45.0% |
| Q1 FY2024 | Mar 31, 2024 | $143.82M | -60.3% |
| Q4 FY2023 | Dec 31, 2023 | $143.89M | -64.1% |
| Q3 FY2023 | Sep 30, 2023 | $157.19M | -64.0% |
| Q2 FY2023 | Jun 30, 2023 | $246.42M | -42.6% |
| Q1 FY2023 | Mar 31, 2023 | $362.42M | -16.5% |
| Q4 FY2022 | Dec 31, 2022 | $401.07M | -3.2% |
| Q3 FY2022 | Sep 30, 2022 | $437.12M | -2.5% |
| Q2 FY2022 | Jun 30, 2022 | $429.34M | +234.3% |
| Q1 FY2022 | Mar 31, 2022 | $434.20M | +48.7% |
| Q4 FY2021 | Dec 31, 2021 | $414.13M | -3.9% |
| Q3 FY2021 | Sep 30, 2021 | $448.29M | +53.3% |
| Q2 FY2021 | Jun 30, 2021 | $128.42M | -56.1% |
| Q1 FY2021 | Mar 31, 2021 | $291.93M | -0.2% |
| Q4 FY2020 | Dec 31, 2020 | $431.01M | +47.8% |
| Q3 FY2020 | Sep 30, 2020 | $292.37M | +0.6% |
| Q2 FY2020 | Jun 30, 2020 | $292.41M | +0.9% |
| Q1 FY2020 | Mar 31, 2020 | $292.62M | +167631.8% |
| Q4 FY2019 | Dec 31, 2019 | $291.61M | – |
| Q3 FY2019 | Sep 30, 2019 | $290.77M | – |
| Q2 FY2019 | Jun 30, 2019 | $289.72M | – |
| Q4 FY2018 | Dec 31, 2018 | $174.46K | – |
See a number that looks wrong?